Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
The purpose of this prospective observational registry is to monitor safety of eribulin in routine clinical practice. Additionally, this study will also assess the effectiveness of eribulin in real-life settings.
Breast Cancer
Number of participants with adverse events (AEs) and serious adverse events (SAEs), Safety assessment will consist of monitoring of all AEs, including SAEs at every visit. All participants will be evaluable for safety from the time of their first treatment with eribulin., From date of first administration of study drug up to 30 days after last administration of study drug or until approximately 2 years
Tumour response, From date of enrollment, Day 1 and Day 8 of every 21 day cycle or up to approximately 2 years|Overall survival (OS), From date of first administration of study drug to date of death or up to approximately 2 years|Demographic and clinical characteristics, Up to approximately 2 years|Duration of treatment, Historical data collected at Baseline|Incidence of dose delays, From date of first administration up to approximately 2 years|Incidence of dose reductions, From date of first administration up to approximately 2 years|Relative dose intensity (RDI) of eribulin, From date of first administration up to approximately 2 years|Treatment patterns for locally advanced or metastatic breast cancer, Historical data collected at Baseline
The purpose of this prospective observational registry is to monitor safety of eribulin in routine clinical practice. Additionally, this study will also assess the effectiveness of eribulin in real-life settings.